Ying is China Commercial Editor with PharmAsia News. She has been working with international healthcare business intelligence since 2007, covering China and South East Asian countries including Singapore, Taiwan, Thailand, Vietnam, the Philippines, Malaysia and Indonesia. Her work covers health care reform, new drug development, M&A and financing, partnering, business strategies and outsourcing.
Prior to joining Informa, Ying was the China Bureau Editor of BioPharm Insight, a Financial Times Group product. She led the investigative coverage on the important situations taking place within the healthcare industry, delivering breaking news and insights on the biopharmaceutical industry in China and Southeast Asia.
Ying has covered academic and industry meetings in China and Asia where she has interviewed C-level executives and key opinion leaders. She has also worked as an international business development assistant at a China-listed pharmaceutical company.
Ying holds a Master's degree in Public Health from the University of Westminster in London, and a bachelor’s degree in biotechnology.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ying Huang
The strategic alliance between Amgen and Simcere Pharmaceutical to develop biosimilars in China was officially kicked off in Nanjing city last week, amid heightened excitement around China’s newly issued opinions on deepening reforms to encourage drug innovation including biosimilars. With the favorable opportunities, Amgen is open to establishing more local partnerships as its core China strategy.
In contrast to GSK’s online-to-offline approach to promote its HPV vaccine, Merck is going the conventional route and tapping into the Chinese market via a domestic partner for Gardasil and other vaccines. Its partner Zhifei Biological is accelerating an expansion of its direct sales team to extend its reach.
With overseas revenues rising sharply in the first half of 2017, Fosun Pharma expects to build on its global investment strategy at a fast pace, striking more deals to acquire products and companies from developed markets.
China’s Fosun group isn’t backing off from its $1bn-plus buyout of Gland Pharma and will now pursue a tweaked version of the original deal that technically qualifies for automatic approval under Indian rules. Whether that means smooth sailing hereon remains unclear.
Merck adds to its immuno-oncology R&D heft with purchase of Rigontec, while Allergan will collaborate with Lyndra to produce once-weekly drugs for Alzheimer’s disease.
French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.